Table 2.

Association of Biomarker Levels With cGVHD in Verification Cohort 1 (178 patients and 33 controls)

Model	OR* (95% CI)	P	AUC†
Single biomarkers
ST2	104 (17 to 623)	< .001	0.83
MMP3	11.6 (4.1 to 33)	< .001	0.79
TNFRSF10C	68.0 (7.5 to 617)	< .001	0.72
OPN	11.7 (3.8 to 36)	< .001	0.71
SELP	22.8 (2.3 to 227)	.005	0.66
CKIT	0.06 (0.007 to 0.45)	.004	0.65
COMP	9.6 (1.7 to 53)	.006	0.64
CXCL9	3.5 (1.2 to 10)	.02	0.63
CD146	39.5 (1.4 to 999)	.03	0.62
Best combination of biomarkers
ST2	25.4 (3.6 to 180)	< .001	0.89
CXCL9	6.1 (1.5 to 24)
MMP3	5.2 (1.5 to 18)
OPN	4.8 (1.2 to 19)
Single biomarkers with clinical covariates‡
ST2	124 (18 to 857)	< .001	0.85
MMP3	11.7 (3.8 to 36)	< .001	0.80
TRAILR3	91.9 (8.2 to 999+)	< .001	0.77
OPN	14.5 (4.1 to 52)	< .001	0.79
SELP	31.5 (2.8 to 357)	.003	0.73
CKIT	0.06 (0.006 to 0.54)	.008	0.73
COMP	25.4 (3.2 to 200)	.008	0.74
CXCL9	4.5 (1.4 to 14.3)	.009	0.71
CD146	47.2 (1.3 to 999)	.03	0.70
Best combination of biomarkers with clinical covariates‡
ST2	70.2 (6.5 to 761)	< .001	0.92
CXCL9	26.9 (3.9 to 186)
MMP3	7.9 (2.0 to 30.9)
OPN	11.9 (2.1 to 68.5)

Abbreviations: AUC, area under the curve; cGVHD, chronic graft-versus-host disease; OR, odds ratio.

^*OR per log increase in biomarker, estimated using logistic regression.

^†AUC calculated from logistic regression; includes clinical covariates in model where indicated.

^‡AUC with clinical covariates only: 0.66.